Bayer begins $240m AI drug discovery project with Exscientia

Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Bayer targets Amazon sellers over fake products

5 September 2023 Healthcare company accuses online sellers of selling unauthorised over-the-counter products | Consumers leave bad reviews after receiving damaged, expired and poor quality goods, says the complaint | Vory, Sater, Seymour and Pease.

Plant Varieties

Rival sues Monsanto, Bayer over GM plant tech

11 August 2022 Firms accused of using GM tech for herbicide-resistant plants | Plaintiff says its patented tech helps farmers to innovate | US District Court for the District of Delaware.

Americas

Bayer to spend up to $4bn on Asklepios BioPharmaceutical

27 October 2020 Germany-based Bayer will pay up to $4 billion to acquire gene therapy company Asklepios BioPharmaceutical.